Asabys Partners — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Agomab Therapeuticsagomab.cominJul 2022
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.
BiotechHealthtechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)in
Co-investorsEQT Life SciencesAdBio partnersAndera PartnersCanaan PartnersPontifax Venture CapitalV-Bio Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.